🧬 EGFRm NSCLC – COMPEL trial OSI + chemo vs PBO + CT after 1L PD (non-CNS): •PFS ↑ HR 0.43 → 8.4 vs 4.4m •OS trend HR 0.71 → 15.9 vs 9.8m •Benefit extends beyond CNS ‼️ trials was early ✋🏻 BUT is informative IASLC OncoAlert #wclc25

AEGEAN patterns of progression. Adding Perioperative durva to neoadj CT reduced PD precluding/preventing completion of surgery and locoregional and distant post-surgery recurrences. Time to recurrence was longer with perioperative durva.Fundación Jiménez Díaz OncoAlert #WCLC25 #LCSM

🚨 #WCLC25 | EA5181 Trial In unresectable stage III #NSCLC, adding concurrent durvalumab to CRT (vs CRT alone → durva consolidation) showed: ❌ No OS benefit – HR 1.03 (95% CI 0.80–1.32) ❌ No PFS benefit – HR 1.05 (95% CI 0.86–1.29) ❌ No change in recurrence or ORR 🔑 PACIFIC

Data for NADIM-Adjuvant was presented at #WCLC25. NeoAdj by Patrick Forde (or PeriOP/PostOp approach) with chemo-IO remains the SoC at this time for resectable NSCLC. If this gets approved, will wait for Eric K. Singhi, MD official slide update! #OncTwitter #MedTwitter #lcsm

The need for pneumonectomy should not be considered a criterion for unresectability, and thus should not be used as a justification for CRT. In CheckMate 816, patients who underwent pneumonectomy had a 5-year OS of 80%!

The CheckMate 816 study showed that using NIVO + chemo before surgery significantly improves long-term survival for resectable NSCLC patients. The data highlights strong 5-year overall survival benefits, even for patients who underwent extensive surgeries like pneumonectomy.

In 1st L, subcut. amivantamab ➕ CT works in EGFR ex20ins 🫁 similar to iv amiva. Despite sc amiv. reduces infusion reactions,the skin/paronychia EGFR-related toxicity remains the most common.Perhaps future in 1st L🔮EGFRex20ins TKI —> sc ami + TKI (TVE risk?)—> Chemo #WCLC2025

#WCLC25 Highlights #CommunityOncology: 1. #FLAUR2 1L EGFR mNSCLC d.planchard 2. #ACROSS2 1L EGFR mNSCLC Jordi Remon 3. #HARMONi 2L EGFR NSCLC 4. #ALCHEMIST Adj ALK+ NSCLC 5. #NadimAdjuvant Adj ChemoIO NSCLC #lcsm #OncTwitter IASLC Jarushka Naidoo Noemi Reguart Isabelle Opitz 1/6

🚨🔥OncoAlert Hot Off The Press. Just published JTO & JTO CRR, results of: ⭐️ #COCOON Trial 🔷The Very important #SupportiveCare randomized trial of: Enhanced Vs Standard #Prophylactic #Dermatologic Management during Tx with #Amivantamab/#Lazertinib in patients with #EGFR+

Best slides of #WCLC25? Daniel Tan’s elegant discussion of #FLAURA2 in the context of the journey of EGFR+ NSCLC, incremental gains from sequential therapies, & the key factors informing decision making at clinical inflection points IASLC EGFR Resisters OncoAlert #LCSM

🧠 Neurotoxicity in Cancer Therapy New review (Nat Rev Clin Oncol) by Philipp Karschnia Peripheral Nerve Society (PNS) SNO Mass General Brigham Research Mass General Cancer Center ✅ Pathophysiology of chemo-, RT- & IO-induced neurotoxicity ✅ Clinical recognition & biomarkers ✅ Prevention & management strategies

Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection ilcn.org/interim-nadim-…

Abiraterone 250mg vs. 1000mg? Multiple studies continue to show similar efficacy and ⬇️ cost (though through Mark Cuban Cost Plus Drug Company Mark Cuban, cost has gone ⬇️ significantly…), should the lower dose be the SoC in CRPC and higher dose be used as a back-up? #OncTwitter #gusm JCO Global Oncology

The first, evidence-based ESMO-ESTRO consensus statements to guide the combination of RT with targeted cancer therapies and immunotherapy!!! They have expected that the toxicity of combining RT with ICIs is low, particularly for PD-(L)1 inhibitors. For most combinations with

Qué peliculón tan bravo es #OneBattleAfterAnother Debió estar en producción mucho tiempo, parece escrita para esta mañana. Pasan cosas desde el minuto 1, es de esas que no dan respiro. Las actuaciones son todas de 10. Sean Penn de loco perverso, otro nivel. Un humor ácido y

💫🌟🚨 Ann Oncol ESMO–ESTRO Consensus Safety of combining RT with systemic therapies Authors: @GPentheroudaki umberto ricardi giuseppe Minniti Angela Lamarca OncoAlert 🔑 Key messages: 🔵 ICI + RT: Feasible in selected scenarios, but monitor for ↑risk pneumonitis & late

Esta mañana, en una actividad académica en Medellín, uno de los ponentes recomendó el uso rutinario de PET-CT en la estadificación de pacientes con cáncer de mama HER2 positivo (creo, para ser justos, que era en etapa II). Cuando lo interpelé sobre que en el Consenso de

Intensification 1st L Tt in EGFRm mNSCLC is SoC. Poor prognosis pts obtain benefit of intensification in PFS but also OS (FLAURA 2 data) Hwr, only 40% real population suitable to intensification. Then patient w/o poor prognosis should Osi monotherapy continue be 1st L? #ESMO2025

Review in JAMA on lung cancer in patients with no smoking history, who now make up about 20% of all new cases of lung cancer. The biology of these cancers is different, as is the treatment, but the gravity is the same. Read now at JAMA. jamanetwork.com/journals/jama/…

Laura Lo mismo pensó por 15 segundos mi papá antes de comprarme una calculadora Texas Instruments en 1976 cuando tenía 12 años. La verdad, nunca más saqué una raíz cuadrada que tampoco necesité. Con ella aprendí a programar - y con programación - años después, formamos una compañía con